ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

AAMI Releases Alternative Guidance for Radiation Sterilization

Arlington, Virginia, July 29, 2024 (GLOBE NEWSWIRE) -- Right now, pharmaceutical and biopharmaceutical manufacturers often rely on outdated best practices related to radiation sterilization and routine control of single-use systems. But there is new industry guidance that will help streamline these processes.

The Association for the Advancement of Medical Instrumentation (AAMI) is pleased to announce the release of a new guidance document that updates best practices for manufacturers of pharmaceuticals and biopharmaceuticals.

The new guidance outlines acceptable alternative approaches to radiation sterilization validation and routine control for single-use systems. It is a Consensus Report, a document type based on expert opinion that AAMI uses to provide quick and practical guidance on urgent issues.

AAMI CR513:2024; Guidance on radiation sterilization validation and routine control of single-use systems used for pharmaceutical and biopharmaceutical manufacturing was produced by the AAMI Radiation Sterilization Working Group, a diverse team of sterilization and sterile processing professionals, regulators, and scientists. The group is co-chaired by Niki Fidopiastis, director of microbiology for Global Laboratory Services at Medtronic, and Kimberly Patton, sterilization staff engineer and auditor of the MedAccred Program at the Performance Review Institute.

AAMI CR513:2024 provides guidance on:

  1. Sterilization dose, addressing which products should be selected for testing, and best practices for testing.
  2. Sterile claim, providing guidance on estimating sterility assurance level and selecting sterile claims.
  3. Dose application, including information on the proper delivery of a verification dose and sterility testing.
  4. Risk assessment, establishing the components of risk assessment for single-use systems, considering each system’s needs.
  5. User verification, focusing on how to independently verify the sterility assurance level of a single-use system.

According to Fidopiastis, AAMI CR513 is a much-needed stopgap, and its “simplified approaches for validation and routine control of single-use systems” will provide manufacturers with the clear guidance they need.

Patton agreed, stating, “The current practices as written for radiation sterilization validation and control testing can be difficult to implement for large, complicated single-use systems and are often cumbersome and can lead to contamination in the test vessels. They are also overly conservative in some cases where large equipment might not come into contact with the patient.”

Ultimately, AAMI CR513 is an ideal resource for manufacturers interested in improving their processes and continuing to produce safe products.

The document can be accessed or purchased on AAMI ARRAY. Journalists interested in a copy of the guidance are encouraged to reach out to the AAMI Media Team via dvisnovsky@aami.org.


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.